Abstract 1299P
Background
Obesity has been associated with favorable outcomes in patients (pts) with Non-Small Cell Lung Cancer (NSCLC) treated with Immune Checkpoint Inhibitors (ICIs). We conducted a prospective observational study in order to investigate the effect of differential fat tissue compartment compositions on treatment outcomes in ICI treated NSCLC patients.
Methods
Pts with non-oncogenic driven metastatic NSCLC treated with ICIs were included in the study. Adipose tissue compartment composition was calculated by measuring the fat densities at the level of 3rd lumbar vertebra in each pts’ computed tomography scan before ICI initiation using sliceOmatic tomovision. We converted the densities to indices [Intramuscular Fat Indice (IMFI), Visceral Fat Indice (VFI), Subcutaneous Fat Indice (SFI)] by dividing them by height in meters squared. Patients were dichotomized based on their baseline IMFI, VFI and SFI according to their gender specific median value.
Results
52 pts were included in the final analysis. 43 patients were males, median follow-up was 9.9 months and median overall survival (OS) was 10.33 months (95% CI: 6.83-13.84). SFI values distribution was significantly higher (p=0.040) in responders compared to non-responders to ICIs. None of the other variables affected response rates. SFI as a continuous variable HR: 0.983 (95% CI:0.970-0.997, p=0.014) was significantly positively associated with increased OS. Low SFI: 2.20 (1.114-4.333, p=0.023) consisted an independent predictor for inferior OS in the multivariate Cox Regression Analysis. VFI HR:1.50 (0.769-2.919, p=0.235) and IMFI HR: 1.50 (0.770-2.931, p=0.232) values did not affect survival outcomes in our cohort.
Conclusions
Adipose tissue composition affects immunotherapy outcomes and it could be utilized as a potential biomarker. Our findings merit evaluation in larger cohorts. Further research is needed in order to decipher the interrelation between adiposity and antitumor immunity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
ARSA.
Disclosure
All authors have declared no conflicts of interest.